Patent Application
20210204503
A Sequence Listing submitted as an ASCII text file via EFS-Web is hereby incorporated by reference in accordance with 35 U.S.C. § 1.52(e). The name of the ASCII text file for the Sequence Listing is 2020-08-15_Substitute sequence listing_DAVIE70.002APC.TXT, the date of creation of the ASCII text file is Aug. 15, 2020, and the size of the ASCII text file is 100.4 KB.
The present invention relates to medicinal cannabis plants, and cannabis plant-derived products. In particular, the present invention relates to medicinal cannabis plants having a desired cannabinoid content, methods of selecting cannabis plants having a desired cannabinoid content, chemotype and/or sex, extraction therefrom, and uses thereof. The present invention also relates to genetic markers for identifying and selecting cannabis plants having a desired chemotype and/or sex and uses thereof.
The Cannabis plant is an erect annual herb with a dioecious breeding system. Wild and cultivated forms of cannabis are morphologically variable. Presently, it is believed that there are three distinct species in the genus, but the taxonomy remains unclear: Cannabis sativa, Cannabis indica and Cannabis ruderalis. Cannabis sativa is the most commonly known.
Cannabis has a diploid genome (2n=20) with a karyotype composed of nine autosomes and a pair of sex chromosomes (X and Y). Female plants are homogametic (XX) and males are heterogametic (XY) with sex determination controlled by an x-to-autosome balance system. The estimates size of the haploid genome is 818 Mb for female plants and 843 Mb for male plants, owing to the larger size of the Y chromosome.
The cannabis plant (also referred to as marijuana, hemp) has been used for its medicinal and psychoactive properties for centuries. Currently, cannabis and its derivatives such as hashish are the most widely consumed illicit drugs in the world. Hemp forms of the cannabis plants are also used as an agricultural crop for example as a source of fibre. Cannabis use is also increasingly recognized in the treatment of a range of conditions such as epilepsy, multiple sclerosis and conditions with chronic pain.
The unique pharmacological properties of cannabis are mostly due to the presence of naturally occurring compounds known as cannabinoids. Marijuana plants have a high-THCA/low-CBDA chemotype. Hemp plants have a low-THCA/high-CBDA chemotype. There are also large differences in the specific spectrum of minor cannabinoid within these basic chemotypes.
Cannabinoids mainly accumulate in the female flowers or “buds” of the plant. Cannabinoids are also present in natural extracts derived from cannabis plants.
Tetrahydrocannabinol (THC) and cannabidiol (CBD) have been the best characterised cannabinoids to date. THC is the main psychoactive cannabinoid and the compound responsible for the analgesic, antiemetic and appetite-stimulating effects of cannabis. Non-psychoactive cannabinoids such as cannabidiol (CBD), cannabichromene (CBC) and tetra-hydrocannabivarin (THCV), which possess diverse pharmacological activities, are also present in some strains.
Pharmaceutical compositions comprising cannabinoids having specific ratios of CBD to THC are useful in the treatment and management of specific diseases or medical conditions. For example, a pharmaceutical composition containing a high ratio of CBD compared to THC is useful in the field of epilepsy. Conversely, a pharmaceutical composition containing a high ratio of THC compared to CBD is useful in the field of pain relief.
The amount of particular components in the cannabis plant or extracts therefrom may impact the efficacy of therapy and potential side effects. Accordingly, cannabis plant varieties having specific therapeutic component profiles may be useful in the production of pharmaceutical compositions for the treatment of specific conditions.
Current methods for the determination of amounts of cannabinoids in a cannabis plant or extracts therefrom have limitations around resolution sensitivity, reliability and throughput.
There exists a need to overcome, or at least alleviate, one or more of the difficulties or deficiencies associated with the prior art.
In one aspect, the present invention provides a method of identifying a cannabis plant having high THC content and/or high CBD content, wherein the method includes detecting a genetic variation associated with the THCAS gene and/or CBDAS gene in the cannabis plant.
In a preferred embodiment, the method may further include correlating said genetic variation with high THC content and/or high CBD content.
All Cannabinoids, including THC and CBD are derived from the precursor cannabigerolic acid (CBGA).
Several key enzymes have been identified in the cannabinoid pathway that dictate whether the CBGA is converted to cannabidiolic acid (CBDA), tetrahydrocannabinolic acid (THCA) or less commonly, remain as cannabigerolic acid (CBGA) or become cannabichromene acid (CBCA). Decarboxylation then converts THCA into THC, CBDA into CBD and CBCA into CBC. It is in this form that the cannabinoids are generally used for medicinal purposes.
The main two oxidocyclases, THCA synthase (THCAS) and cannabidiolic acid synthase (CBDAS) are involved in the conversion of the CBGA precursor to THCA and CBDA respectively. Therefore, the amount of THCAS versus CBDAS present in a cannabinoid plant can determine the amount each different cannabinoid in a specific cannabis plant. This is also referred to as a THCAS:CBDAS ratio.
Determining the presence or absence of one or more variations of genetic markers associated with the THCAS and/or CBDAS genes in a cannabis plant may be used to identify the relative THCAS and/or CBDCAS that is expressed and the THC/CBD content (or THC/CBD chemotype) in the cannabis plant. The genetic variations are therefore useful in a method to determine the THC/CBD chemotype of a cannabis plant. Additionally, the genetic markers may be used as an effective tool to screen the THC/CBD content at the genetic level. Furthermore, the genetic markers may be used in the application of genome editing to optimise THC/CBD chemotype in a cannabis plant.
The cannabis plant can be selected from the following species (or sub-species) Cannabis sativa, Cannabis indica, Cannabis ruderalis, or hybrid thereof, preferably the cannabis plant is Cannabis sativa.
The term “cannabinoids” as used herein refers to a class of compounds that act on the cannabinoid receptors. Cannabinoids found in the cannabis plants include, without limitation: cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrandrocannabinol (THC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarian (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), d9-THC, exo-THC. 11-OH-d9-THC, 11-nor-d9-THC, d9-THCA-A, d8-THC12
“Terpenes” or “terpenoids” refer to a class of chemicals produced by plants, including cannabis. These compounds are often aromatic hydrocarbons and have strong aroma associated with them. Terpenes known to be produced by cannabis include, without limitation, aromadendrene, bergamottin, bergamotol, bisabolene, borneol, alpha-3-carene, caryophyllene, cinole/eucalyptol, p-cymene, dihyrojasmne, elemene, farnesene, fenchol, geranylacetate, guaiol, humulene, isopulegol, limonene, linalool, menthone, menthol, menthofuran, myrcene, nerylacetate, neomenthylacetate, ocimene, perillylalcohol, phellandrene, pinene, pulegone, sabinene, terpinene, terpinol, terpineol-4-ol, terpinolene, and derivatives, isomers, enantiomers thereof.
The term “high THC content” as used herein refers to the content by weight of cannabinoid THC in an extract that is derived from the cannabis plant which is higher than the CBD content by weight. The ratio by weight of THC to CBD may be more than 1, preferably more than about 1.2, more preferably more than about 1.5, more preferably more than about 2. Preferably the ratio by weight of THC to CBD is between about 400:1 and 2:1, preferably about 100:1 to 2:1, more preferably about 50:1 to 2:1, more preferably about 25:1 to 2:1, more preferably about 10:1 to 2:1, more preferably about 5:1 to 2:1. In some instances “high THC content” may refer to a cannabis plant which does not have any CBD content.
The term “high CBD content” as used herein refers to the content by weight of cannabinoid CBD in an extract that is derived from the cannabis plant which is higher than the THC content by weight. The ratio by weight of CBD to THC may be more than 1, preferably more than about 1.2, more preferably more than about 1.5, more preferably more than about 2. Preferably the ratio by weight of CBD to THC is between about 400:1 to 2:1, preferably about 100:1 to 2:1, more preferably about 50:1 to 2:1, more preferably about 10:1 to 2:1, more preferably about 5:1 to 2:1. In some instances “high CBD content” may refer to a cannabis plant which does not have any THC content.
The term “chemotype” as used herein is meant to refer to the content of chemical compounds found in the cannabis plant. This includes, but not limited to the presence and/or absence of specific cannabinoids found in an extract of the cannabis plant. For example, the CBD/THC chemotype as used herein refers to the CBD and/or THC content found in the cannabis plant. This also includes the presence or absence of other compounds, including cannabinoids in addition to or other than THC/CBD, and terpenes or terpinoids.
Accordingly, in a further aspect of the invention, the cannabis plant further includes one or more cannabinoids selected from the group consisting of: cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrandrocannabinol (THC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarian (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid(CBDA), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), d9-THC, exo-THC. 11-OH-d9-THC, 11-nor-d9-THC, d9-THCA-A, d8-THC12.
Accordingly, in a further aspect of the invention, the cannabis plant further includes terpenes. Preferably, the terpenes are selected from one or more of the following group: aromadendrene, bergamottin, bergamotol, bisabolene, borneol, alpha-3-carene, caryophyllene, cinole/eucalyptol, p-cymene, dihydrojasmone, elemene, farnesene, fenchol, geranylacetate, guaiol, humulene, isopulegol, limonene, linalool, menthone, menthol, menthofuran, myrcene, nerylacetate, neomenthylacetate, ocimene, perillylalcohol, phellandrene, pinene, pulegone, sabinene, terpinene, terpinol, terpineol-4-ol, terpinolene, and derivatives, isomers, enantiomers thereof.
The term “genetic variation” as used herein is meant to refer to a change of the DNA, RNA and/or protein sequence. The genetic variation may be, but is not limited to, a single polynucleotide change in the DNA sequence. The genetic variation may also result in other changes in the protein expression level, including premature stop codons that result in truncated proteins. The function of the resulting protein that is expressed may or not be affected.
The genetic variation may be detected by various techniques, including detecting the presence or absence of polymorphic markers such as simple sequence repeats (SSRs) or mating type gene markers. Alternatively, or in addition, the genetic variation may be detected by sequencing genomic and/or mitochondrial DNA and/or ribosomal RNA, and performing sequence comparisons to databases of known nucleic acid sequences, for example known sequences of the THCAS and/or CBDAS genes.
The analysis of genetic variation may be performed on nucleic acid samples obtained from the cannabis plant. Preferably the nucleic acid samples may be extracted from the buds, leaves or flowers of the cannabis plant. The nucleic acid samples maybe DNA or RNA. Only small amounts are required for analysis and suitable for automation.
In one aspect of the present invention, the genetic variation is associated with the THCAS gene.
In one embodiment of this aspect of the invention, the genetic variation results in one or more amino acid changes in the expression of the THCAS gene. Preferably the genetic variation is selected from either one or both: Lys to Met at position 8190 and Leu to Phe at position 8201 in the THCAS gene. The applicant has found that the variation in the DNA sequence of the THCAS gene in either one or both of these two positions results in amino acid changes in the THCAS. Without being bound by any particular theory or mode of action, it is believed that this genetic variation may play a role in methylation patterns.
In another embodiment, the genetic variation is associated with the CBDAS gene.
Genetic variations or mutations resulting in a premature stop codon in the expression of the CBDAS gene have been identified and described in van Bakel et al (2011). The applicant has now quantified these from a pan genome evaluation of the cannabis plant.
In another aspect of the invention there is provided a cannabis plant having a high THC content and/or high CBD content. Preferably, the cannabis plant is identified according the method described herein.
In one embodiment of this aspect of the invention, there is provided a cannabis plant wherein the CBD is present in the cannabis plant in an amount by weight greater than the amount by weight of THC. In some embodiments, the cannabis plants do not have any THC.
In another embodiment of this aspect of the invention, there is provided a cannabis plant wherein the THC is present in the cannabis plant in an amount by weight greater than the amount by weight of CBD. In some embodiments, the cannabis plants do not have any CBD.
In another embodiment of this aspect of the invention, there is provided a seed, cell, part of a plant and/or a plant-derived product derived from a plant according to the present invention. A plant-derived product may be but not limited to an oil, tincture, flowers, buds and/or leaves. The flowers and/or leaves maybe dried or cured.
The cannabis plant identified according to the invention is useful in breeding cannabis strains for medicinal purposes, or medicinal cannabis. Medicinal cannabis strains are useful for the preparation of pharmaceutical composition containing the desired amount of cannabinoids, preferably medicinal cannabis strains having a high THC content and/or high CBD content.
Accordingly, in another aspect there is provided a method of breeding a cannabis plant including the step of identifying or selecting a cannabis plant having high THC content and/or high CBD content as herein described.
In a preferred embodiment, the method may further include propagating or crossing the selected plant.
In a further aspect there is provided a use of a cannabis plant having high THC content and/or high CBD content identified by the methods described herein for breeding a medicinal cannabis plant.
In another aspect of the invention there is provided a method of preparing a composition which includes the steps of:
Preferably the composition is a pharmaceutical composition. Preferably the method includes the further step of combining the extract with one or more pharmaceutical excipients.
In one preferred embodiment of this aspect of the invention, the composition further includes one or more other cannabinoids selected from: cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrandrocannabinol (THC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarian (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), d9-THC, exo-THC. 11-OH-d9-THC, 11-nor-d9-THC, d9-THCA-A, d8-THC12, preferably CBDA and THCA.
Preferably, the composition further includes one or more terpenes selected from the group consisting of aromadendrene, bergamottin, bergamotol, bisabolene, borneol, alpha-3-carene, caryophyllene, cinole/eucalyptol, p-cymene, dihydrojasmone, elemene, farnesene, fenchol, geranylacetate, guaiol, humulene, isopulegol, limonene, linalool, menthone, menthol, menthofuran, myrcene, nerylacetate, neomenthylacetate, ocimene, perillylalcohol, phellandrene, pinene, pulegone, sabinene, terpinene, terpinol, terpineol-4-ol, terpinolene, and derivatives, isomers, enantiomers thereof.
In another preferred embodiment, the method further includes the step of heating plant material of (a) to a temperature of from about 60° C. to about 225° C., preferably about 100° C. to about 150° C., more preferably about 110° C. to 130° C., more preferably at about 120° C., to decarboxylate the acid form of any cannabinoids present in the extract.
In another preferred embodiment, the extract is prepared by at least one of the following procedures: maceration, percolation, extraction with a solvent or supercritical fluid extraction.
In another preferred embodiment of the invention the composition is further formulated into a pharmaceutical composition.
In another aspect of the invention, there is provided a pharmaceutical composition prepared by the methods described herein.
In one embodiment of this aspect, there is provided a pharmaceutical composition wherein CBD is present in an amount by weight greater than THC. In some embodiments, the composition does not contain any THC.
In another embodiment of this aspect of the invention, there is provided a pharmaceutical composition wherein the THC is present in an amount by weight greater than CBD. In some embodiments, the composition does not contain any CBD.
Preferably, the composition further includes one or more other cannabinoids selected from cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrandrocannabinol (THC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarian (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), d9-THC, exo-THC. 11-OH-d9-THC, 11-nor-d9-THC, d9-THCA-A, d8-THC12.
Preferably, the composition further includes one or more terpenes selected from the group consisting of aromadendrene, bergamottin, bergamotol, bisabolene, borneol, alpha-3-carene, caryophyllene, cinole/eucalyptol, p-cymene, dihydrojasmone, elemene, farnesene, fenchol, geranylacetate, guaiol, humulene, isopulegol, limonene, linalool, menthone, menthol, menthofuran, myrcene, nerylacetate, neomenthylacetate, ocimene, perillylalcohol, phellandrene, pinene, pulegone, sabinene, terpinene, terpinol, terpineol-4-ol, terpinolene, and derivatives, isomers, enantiomers thereof.
In another aspect of the invention there is provided a pharmaceutical composition for use in the manufacture of a medicament for the treatment of a medical condition. Preferably the medical condition is pain relief or management thereof or epilepsy.
Alternatively, in another aspect of the invention there is provided a pharmaceutical composition for use in the manufacture of a medicament for the treatment of a therapeutic condition. Preferably the therapeutic condition is pain relief or management thereof or epilepsy.
THC has an analgesic, anti-spasmodic, anti-tremor, anti-inflammatory, appetite stimulant and anti-emetic properties whilst CBD has anti-inflammatory, anti-convulsant, anti-psychotic, anti-oxidant, neuroprotective and immunomodulatory effects.
Pharmaceutical compositions comprising cannabinoids having specific ratios of CBD to THC are useful in the treatment and management of specific diseases or medical conditions. For example, a pharmaceutical composition containing a high ratio of CBD compared to THC is useful in the field of epilepsy. Conversely, a pharmaceutical composition containing a high ratio of THC compared to CBD is useful in the field of pain relief.
According to this aspect of the invention, a composition having CBD in an amount by weight greater than the amount by weight of THC may be used in the treatment of epilepsy.
According to another aspect of the invention, a composition having THC in an amount by weight greater than the amount by weight of CBD is used in the treatment of pain and/or management thereof.
In a further aspect of the present invention there is provided use of a composition according to the present invention for the treatment of a therapeutic condition, wherein the therapeutic condition is epilepsy.
In a further aspect of the present invention there is provided a method of treating a therapeutic condition including the administration of a composition according to the present invention to a patient in need of treatment, wherein the therapeutic condition is epilepsy.
In these aspects of the present invention, preferably the CBD is present in the composition in an amount by weight greater than the amount by weight of THC.
In a further aspect of the present invention there is provided use of a composition according to the present invention for the treatment of a therapeutic condition, wherein the therapeutic condition is pain relief or management thereof.
In a further aspect of the present invention there is provided a method of treating a therapeutic condition including the administration of a composition according to the present invention to a patient in need of treatment, wherein the therapeutic condition is pain relief or management thereof.
In these aspects of the present invention, preferably the THC is present in the composition in an amount by weight greater than the amount by weight of CBD.
The present invention will now be more fully described with reference to the accompanying Examples and drawings. It should be understood, however, that the description following is illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.
In the Figures:
The invention will now be described with reference to the following non-limiting examples.
Assays for the determination of chemotype and plant sexing currently exist as shown in
The DNA marker assay for determining cannabinoid content was performed as described in Pacifico et al (2006). 3 PCR primer reaction amplifies a pair of products from the THCAS and CBDAS genes. The presence of the band is linked with the functional variant of the gene and therefore the assay indicates the THC/CBD chemotype of the cannabis plant.
The DNA marker assay for determining plant sex was performed as described in Mandolino et al (1999). The assay is a PCR based primer reaction—the size of the product indicates whether the plant is male or female.
There are limitations with these methods as this is based on technology with limitations around: resolution, sensitivity, reliability and throughput.
Current genomic resources for Cannabis plants are not well described. A draft genome and transcriptome sequence of C. sativa, Purple Kush (PK) a marijuana strain that is widely used for its medicinal effects has been reported (Van Bakel et al (2011)).
Through the availability of short-read sequencing technology a cohort of around 200 medicinal cannabis plants have now been genome sequenced. The cannabis strains analysed include: Opium; Durga Mata; Durga Mata II; Wappa; Nebula; Spoetnik; Ali Kush; Ice Cream; White Berry; Sensi Star.
Genome sequencing was performed using short sequence read technology through the Illumina HiSeq300 platforms. DNA from subject plants was enzymatically sheared using the ShredF method (Shinozuka et al (2015)), synthetic DNA adaptors were then ligated and the molecules amplified and then processed on the Illumina platforms using manufacturer's instructions. The resulting DNA sequence was aligned to the reference genome reported in van Bakel et al (2011). DNA sequence variants were then determined and filtered for high quality/confidence base variants.
Over 170 plants from more than 15 accessions have been analysed. Accessions showed varying degree of diversity, including: high CBD producing plants; CBD/THC producing plants; and high THC producing plants. See
Initial genome sequencing identified >24 million variant single nucleotide polymorphisms (SNPs). >2.7 million of these provide high quality variant sites in the genome that can be utilised in the Cannabis genome.
Whole genome sequence data of the strains analysed allows the analysis of the THC-synthase gene (THCAS). The THCAS gene sequence is shown in SEQ ID NO: 1. The corresponding protein sequence is shown in SEQ ID NO: 2. Both sequences are reproduced from genbank:AB057805.
THCAS sequence [genbank:AB057805] [to query the PK genome, a single scaffold of 12.6 kb (scaffold19603, [genbank: JH239911] corresponding to SEQ ID NO: 7) was identified that contained the THCAS gene as a single 1638 bp exon with 99% nucleotide identity to the published THCAS sequence. Querying the PK transcriptome returned the same THCAS transcript (PK29242.1, [genbank:JP450547] corresponding to SEQ ID NO: 9) that was found to be expressed at high abundance in female flowers. Also there is a THCAS-like pseudogene (scaffold1330 [genbank: JH227480] corresponding to SEQ ID NO: 10, 91% nucleotide identity to THCAS)
SNP loci have been identified in the THCAS gene that alter amino acids. Plants having high CBD were found to with a single nucleic acid change resulting in amino acid change from Lysine to Methionine at base 8190 and Leucine to Phenylalanine at base 8201 in scaffold 19603. See
The nucleic acid changes are shown in the 120 bp fragment of the THCAS gene of
A nucleic acid change at position 8190 corresponds to highlighted change A to C. A nucleic acid change at position 8201 corresponds to C to T.
Without being bound by any particular theory, it is believed that the change in amino acid sequence in the THCAS may play a role in methylation patterns. This may influence the level of the cannabinoid THC in the plant that is converted from the CBGA precursor.
Whole genome sequence data of the strains analysed allows the analysis of the CBD-synthase gene (CBDAS). The CBDAS gene sequence is shown in SEQ ID NO: 4. The corresponding protein sequence is shown in SEQ ID NO: 5. Both sequences are reproduced from genbank:AB292682.
CBDA synthase (CBDAS) sequence [genbank:AB292682] to query the PK genome as many as three scaffolds that contain CBDAS pseudogenes (scaffold39155 [genbank:AGQN01159678] corresponding to SEQ ID NO: 8, 95% nucleotide identity to CBDAS; scaffold6274 [genbank:JH231038] corresponding to SEQ ID NO: 11+scaffold74778 [genbank:JH266266] corresponding to SEQ ID NO: 12 combined, 94% identity; and scaffold99205 [genbank: AGQN01254730] corresponding to SEQ ID NO: 13, 94% identity), all of which contained premature stop codons and frameshift mutations. See, van Bakel et al. (2011).
The reference genome sequence from Purple Kush (PK) contains 4 stop codons at the base positions listed in TABLE 1 above within the scaffold 39155 compared to the reference CBDAS sequence in GenBank. Table 1 details the proportion of the samples from the pan genome analysis of cannabis plants of varying chemotypic classes that contain the reference sequence allele (stop codons in this case) versus the alternative allele (Alt) (functional amino acid producing codon). Light grey shading indicates samples with 0% and dark grey shading indicates samples with >50%. No shading indicate samples between 0% and 50%. High CBD content strains do not contain any samples that are only the reference allele at any of the positions, whilst the high THC content strains, with little or no CBD production are almost exclusively containing the reference non-functional alleles at each of the 4 positions.
Without being bound by any particular theory, it is believed that the change in nucleic acid sequence at any one of these positions results in premature stop in the expression of the CBDAS gene. This may influence the level of cannabinoid CBD in the plant that is converted from the CBGA precursor.
Both cannabinoids and terpenes are manufactured in the small resin glands present on the flowers and the main fan leaves of late-stage cannabis plants called trichomes. Trichomes are microscopic, mushroom-like protrusions from the surface of the buds, fan leaves and even on the stalk of the plants. It is within the head of these protrusions where cannabinoids and terpenes are produced in the cannabis plant.
Analysis of transcriptome and metabolome in the specific resin-producing cells from the trichome is possible through cell capture laser capture micro-dissection.
Plant tissue culture techniques have been developed to enable:
See
The metabolome of medicinal cannabis has been analysed, that is an assessment of endogenous metabolites in each strain. Analytical platforms that have been used include
Terpenes or terpenoids are volatile unsaturated hydrocarbons found in plants. These are responsible for the aroma differences between cultivars. Some are bioactive and are believed to contribute to the “entourage effect”.
Air-dried and cured plant material were prepared for analysis. The air-dried buds were coarsely ground and placed into a vial for analysis. A second sample of the same material was cured (heated at 120° C. for 2 hours), cooled and placed into another vial for analysis. The material was left in each sealed vial for several hours to allow the volatiles to equilibrate between the dried material and headspace. For static headspace analysis 1 ml was sampled from the headspace of each vial. For SPME the fibre was exposed to the vial headspace for 20 sec.
Monoterpenes (
Liquid chromatography mass spectrometry (LCMS) allows the identification of cannabinoids by high resolution mass spectra and fragmentation.
UHPLC-PDA (an analytical method using high performance liquid chromatography equipped with photodiode array detector) is used to quantify cannabinoids present in each sample extracts derived from specific cannabis strains. Protocols have been developed to standardise analysis methods under GMP requirements.
The protocols can be used to differentiate between strains (
NMR spectra for cannabinoids have been determined.
SFE uses liquid carbon dioxide to extract cannabinoids from either resin or cured biomass derived from the cannabis plant. TABLE 2 below shows the design of experiment principles applied to optimise extraction of CBD and THC cannabinoids.
TABLE 3 below shows the optimised extraction conditions for cannabis strains
Finally, it is to be understood that various alterations, modifications and/or additions may be made without departing from the spirit of the present invention as outlined herein.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2017903047 | Aug 2017 | AU | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/AU2018/050803 | 8/1/2018 | WO | 00 |
